A Randomized Treatment Trial: Single Versus 7-Day Dose of Metronidazole for The Treatment of Trichomonas Vaginalis Among HIV-Infected Women

• DOI: 10.1097/qai.0b013e3181eda955
• Publication Date: 2010-08-03T16:08:57Z
• Authors: Patricia Kissinger; Leandro Mena; Judy Levison; Rebecca A Clark; Megan Gatski; Harold Henderson; Norine Schmidt; Susan L Rosenthal; Leann Myers; David H Martin
• Keywords: Trichomoniasis; Trichomonas Vaginitis

Objective: To determine if the metronidazole (MTZ) 2-gm single dose (recommended) is as effective 7-day 500 mg twice a day (alternative) for treatment of Trichomonas vaginalis (TV) among HIV+ women. Methods: Phase IV randomized clinical trial; women with culture confirmed TV were to arm: MTZ or dose. All given doses deliver their sex partners. Women recultured at test-of-cure (TOC) visit occurring 6-12 days after completion. TV-negative TOC again 3-month visit. Repeat infection rates compared between arms. Results: Two hundred seventy HIV+/TV+ enrolled (mean age = 40 years, ±9.4; 92.2% African American). Treatment arms similar respect age, race, CD4 count, viral load, antiretroviral therapy status, site, and loss-to-follow up. in arm had lower repeat [8.5% (11 130) versus 16.8% (21 125) (relative risk: 0.50, 95% confidence interval 0.25, 1.00; P < 0.05)] 3 months [11.0% (8 73) 24.1% (19 79) 0.46, 0.21, 0.98; 0.03)] single-dose arm. Conclusions: The was more than